Biological
FluBlok clinical trials
Also written UMN-0501.
- studies test it
- 13
- open now
- 0
- in phase 3
- 5
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 5
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 6
Protein Sciences Corporation (3) · UMN Pharma Inc. (2) · Vaxcyte, Inc. (1) · Duke University (1) · The University of Hong Kong (1) · Centers for Disease Control and Prevention (1) · Sanofi (1) · University of Rochester (1)
Often tested with
Tested in the same studies.
Influenza Vaccines (2) · Fluarix (1) · Fluzone High-Dose (1) · Tadalafil (1) · Poly ICLC (1)
Studies
Open first, then newest update. How each study uses FluBlok is read from its arms, and is right about nine times in ten.
Testing it · 13
- Immunogenicity of Influenza VaccinationsCompletedPhase 4Duke UniversityNCT06518577Written as Flublok® (RIV3)
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeActive, not recruitingPhase 3Vaxcyte, Inc.NCT07365826Written as Seasonal Influenza Vaccine (SIV) (Flublok)
- Dynamics of the Immune Responses to Repeat Influenza Vaccination ExposuresCompletedPhase 4The University of Hong KongNCT04576377Written as FluBlok
- Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCPCompletedPhase 4Centers for Disease Control and PreventionNCT03722589Written as Flublok
- Recombinant Influenza Vaccination in U.S. Nursing HomesStatus unknownPhase 4Insight Therapeutics, LLCNCT03965195Written as Recombinant Influenza Vaccine
- Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlokCompletedPhase 3SanofiNCT00539981Written as FluBlok®
- Comparison of Three Licensed Influenza VaccinesCompletedPhase 4University of RochesterNCT03068949Written as FluBlok
- PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCCCompletedPhase 1Donald T. Weed, MD, FACSNCT02544880Written as Anti-Influenza Vaccine
- Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of AgeCompletedPhase 3Protein Sciences CorporationNCT01825200Written as Flublok
- Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIVCompletedPhase 3Protein Sciences CorporationNCT00539864Written as FluBlok Influenza Vaccination
- Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed AdultsCompletedPhase 2UMN Pharma Inc.NCT01195038Written as Recombinant Influenza HA Vaccine (H5N1)
- Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young AdultsCompletedPhase 2UMN Pharma Inc.NCT00980447Written as UMN-0501
- Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy AdultsCompletedPhase 2/3Protein Sciences CorporationNCT00328107Written as Influenza Vaccine, recombinant Hemagglutinin